A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Preprint
Abstract
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and also pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain and other domains, distal to the ACE2 receptor-interaction site. Collectively, our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that can be targeted by peptides and potentially other drug-like molecules. One-Sentence Summary We identify a conserved site on the SARS-CoV-2 spike that can be targeted by a broadly neutralizing macrocyclic peptide.Keywords
This publication has 41 references indexed in Scilit:
- Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike GlycoproteinAnalytical Chemistry, 2020
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyNature, 2020
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19ACS Central Science, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetaseNature Communications, 2020
- Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumoursJournal of Controlled Release, 2020
- Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining ChallengesJournal of the American Chemical Society, 2019
- Aptamers as targeted therapeutics: current potential and challengesNature Reviews Drug Discovery, 2016
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003